menu search

VIVO / Meridian Bioscience Is Not Your Average Life Science Company

Meridian Bioscience Is Not Your Average Life Science Company
100% technical buy signals. 8 new highs and up 15.79% in the last month. Read More
Posted: Jul 5 2022, 22:15
Author Name: Seeking Alpha
Views: 102876

VIVO News  

Medical Devices Stock Pumps Up Buy Point With New Innovations

By Investors Business Daily
November 17, 2022

Medical Devices Stock Pumps Up Buy Point With New Innovations

After launching three new products and posting a second quarter of rising EPS growth, medical devices leader Merit Medical Systems is probing a new bu more_horizontal

Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement

By InvestorPlace
July 7, 2022

Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement

VIVO stock is a hot topic on Wall Street today, not just because Meridian Biosciences released a fiscal update, but also due to takeover news. The pos more_horizontal

Meridian Bioscience Is Not Your Average Life Science Company

By Seeking Alpha
July 5, 2022

Meridian Bioscience Is Not Your Average Life Science Company

100% technical buy signals. 8 new highs and up 15.79% in the last month. more_horizontal

Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

By PRNewsWire
May 23, 2022

Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

CINCINNATI , May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and lif more_horizontal

Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History

By Benzinga
May 6, 2022

Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History

Meridian Bioscience Inc (NASDAQ: VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segmen more_horizontal

Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q2 2022 Results - Earnings Call Transcript

By Seeking Alpha
May 6, 2022

Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q2 2022 Results - Earnings Call Transcript

Meridian Bioscience, Inc. (NASDAQ:VIVO ) Q2 2022 Earnings Conference Call May 6, 2022 10:00 AM ET Corporate Participants Charlie Wood - Vice President more_horizontal

Meridian Bioscience (VIVO) is on the Move, Here's Why the Trend Could be Sustainable

By Zacks Investment Research
May 5, 2022

Meridian Bioscience (VIVO) is on the Move, Here's Why the Trend Could be Sustainable

Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound s more_horizontal

Meridian Bioscience (VIVO) Expected to Beat Earnings Estimates: Should You Buy?

By Zacks Investment Research
April 29, 2022

Meridian Bioscience (VIVO) Expected to Beat Earnings Estimates: Should You Buy?

Meridian Bioscience (VIVO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared more_horizontal


Search within

Pages Search Results: